Herpes Zoster Pipeline Insight

DelveInsight’s, “Herpes Zoster - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Herpes Zoster Understanding

Herpes Zoster: Overview

Herpes zoster, also known as shingles, is a viral syndrome caused by reactivation of the varicella-zoster virus. After an episode of varicella (chicken-pox), the varicella-zoster virus remains dormant in the nervous system. Herpes zoster typically occurs in adults or elderly. It is believed that zoster occurs due to the failure of the immune defense system to control the latent replication of the virus. Upon reactivation, the virus replicates in neuronal cell bodies, and virions shed from the cells which are carried down the nerve to the area of skin innervated by that ganglion. In the skin, the virus causes local inflammation and blistering. The pain caused by zoster is due to inflammation of affected nerves with the virus. Zoster characteristically presents with a prodrome of fever, malaise, and excruciating burning pain followed by the outbreak of vesicles that appear in one to three crops over three to five days. Lesions are distributed unilaterally within a single dermatome. Herpes zoster is clinically diagnosed with burning pain, characteristic morphology, and typical distribution. Antiviral therapy hastens the resolution of lesions, decreases acute pain and helps to prevent post-herpetic neuralgia especially in elderly patients. Acyclovir 800 mg, five times daily for five days, valacyclovir 1 gm three times daily for five days, and famciclovir 500 mg three times daily for seven days are the antiviral drugs used to treat herpes zoster.


"Herpes Zoster - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes Zoster pipeline landscape is provided which includes the disease overview and Herpes Zoster treatment guidelines. The assessment part of the report embraces, in depth Herpes Zoster commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes Zoster collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Herpes Zoster R&D. The therapies under development are focused on novel approaches to treat/improve Herpes Zoster. 

Herpes Zoster Emerging Drugs Chapters

This segment of the Herpes Zoster report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Herpes Zoster Emerging Drugs


Varicella zoster virus vaccine: Changchun BCHT Biotechnology

Changchun BCHT Biotechnology is developing live attenuated varicella vaccine for the prevention of varicella zoster virus infections and herpes zoster. It's a live attenuated herpes zoster vaccine based on the production process of live attenuated chickenpox vaccine. A Phase III clinical trial evaluated live attenuated zoster vaccine to prevent herpes zoster.


EG-HZ: EyeGene

A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA05, an adjuvant system which is a non-toxic LOS-derived substance with optimal immunologic activity. A Phase I clinical trial evaluating the EG-HZ vaccine has been completed.


CRV1O1: Curevo Vaccine

CRV-101 is a next-generation shingles vaccine candidate designed to maximize the CMI protection by combining the gE protein antigen with our proprietary adjuvant. Curevo's CRV-101 is an investigational adjuvanted subunit vaccine for the indication of the prevention of Herpes Zoster in older adults. The adjuvanted subunit vaccine strategy contrasts with traditional approaches using live killed or attenuated viruses. Sub-unit vaccines do not contain virus components and cannot cause infection. The adjuvant component was specifically engineered to produce an optional immune response while using a smaller amount of adjuvant with a targeted structure-function approach. CRV101 is being developed in Phase I stage of development to treat Herpes Zoster.

Further product details are provided in the report……..

Herpes Zoster: Therapeutic Assessment

This segment of the report provides insights about the different Herpes Zoster drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Herpes Zoster

There are approx. 15+ key companies which are developing the therapies for Herpes Zoster. The companies which have their Herpes Zoster drug candidates in the most advanced stage, i.e. Phase III include, Changchun BCHT Biotechnology.


DelveInsight’s report covers around 15+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Herpes Zoster: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Herpes Zoster therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes Zoster drugs.

Herpes Zoster Report Insights

  • Herpes Zoster Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Herpes Zoster Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Herpes Zoster drugs?
  • How many Herpes Zoster drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes Zoster?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Herpes Zoster therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Herpes Zoster and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Herpes Zoster: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Varicella zoster virus vaccine: Changchun BCHT Biotechnology

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

EG-HZ: EyeGene

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical stage products

  • Comparative Analysis

GLS5100: Gene One Life Science

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Herpes Zoster Key Companies

Herpes Zoster Key Products

Herpes Zoster- Unmet Needs

Herpes Zoster- Market Drivers and Barriers

Herpes Zoster- Future Perspectives and Conclusion

Herpes Zoster Analyst Views

Herpes Zoster Key Companies


List of Table

Table 1: Total Products for Herpes Zoster

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Herpes Zoster

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Changchun BCHT Biotechnology Co.
• EyeGene Inc
• Curevo Inc.
• GeneOne Life Science
• Akshaya Bio
• BioNTech/ Pfizer
• CPL Biologicals
• Vaccitech/CanSino
• Shulov Institute for Science LTD
• NanoViricides
• Dynavax
• Turn Therapeutics
• AIM Vaccine
• Xbiotech
• NanoViricides
• NAL Pharma


Forward to Friend

Need A Quote